CLPT logo

ClearPoint Neuro, Inc. Stock Price

NasdaqCM:CLPT Community·US$423.5m Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 22 Fair Values set on narratives written by author

CLPT Share Price Performance

US$14.12
3.15 (28.71%)
US$28.33
Fair Value
US$14.12
3.15 (28.71%)
50.2% undervalued intrinsic discount
US$28.33
Fair Value
Price US$14.12
AnalystConsensusTarget US$28.33
AnalystLowTarget US$25.00
AnalystHighTarget US$30.00

CLPT Community Narratives

·
Fair Value US$28.33 50.2% undervalued intrinsic discount

Minimally Invasive Neurosurgery Will Improve Global Clinical Outcomes

0users have liked this narrative
0users have commented on this narrative
15users have followed this narrative
·
Fair Value US$25 43.5% undervalued intrinsic discount

Regulatory Setbacks In Cell And Gene Therapy Will Eventually Reward Patient Long Term Holders

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
·
Fair Value US$30 52.9% undervalued intrinsic discount

IRRAS Merger And Gene Therapy Ecosystem Will Transform Long Term Neurosurgical Platform Potential

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
US$28.33
50.2% undervalued intrinsic discount
Profit Margin
11.77%
Future PE
130.06x
Price in 2029
US$35.14
US$30
52.9% undervalued intrinsic discount
Profit Margin
12.56%
Future PE
74.06x
Price in 2029
US$37.79

Trending Discussion

No trending discussion available.

Updated Narratives

CLPT logo

CLPT: Huntington’s Disease Partnership Will Drive Future Intracranial Procedure Upside

Fair Value: US$28.33 50.2% undervalued intrinsic discount
15 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
CLPT logo

CLPT: Accelerated Huntington’s Approval Path Will Drive Future Revenue Opportunity

Fair Value: US$25 43.5% undervalued intrinsic discount
0 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
CLPT logo

IRRAS Merger And Gene Therapy Ecosystem Will Transform Long Term Neurosurgical Platform Potential

Fair Value: US$30 52.9% undervalued intrinsic discount
0 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Mediocre balance sheet with low risk.

3 Risks
2 Rewards

ClearPoint Neuro, Inc. Key Details

US$40.6m

Revenue

US$15.3m

Cost of Revenue

US$25.3m

Gross Profit

US$54.4m

Other Expenses

-US$29.1m

Earnings

Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
Aug 03, 2026
-0.97
62.33%
-71.57%
263.5%
View Full Analysis

About CLPT

Founded
1998
Employees
172
CEO
Joseph Burnett
WebsiteView website
www.clearpointneuro.com

ClearPoint Neuro, Inc., a commercial-stage medical device company, focuses on the development and commercialization of platforms for performing minimally invasive surgical procedures in the brain in the United States. The company offers ClearPoint systems, such as ClearPoint hardware, which includes head fixation frame, computer workstation, and in-room monitor; and ClearPoint disposables, which consist of SmartFrame trajectory device, a hand controller and related accessories, and its SmartFlow Neuro cannula. It also provides ClearPoint software, which guides the physician in surgical planning, device alignment, navigation to the target, and procedure monitoring; ClearPoint Prism Neuro laser therapy system to necrotize or coagulate soft tissue; and IRRAflow system, an active fluid exchange platform. In addition, the company offers consulting services to its pharmaceutical and other medical technology partners, such as benchtop testing, preclinical studies, clinical trial support, regulatory consultation, and translation from the preclinical to the clinical setting. It has licenses and collaboration agreements with Koninklijke Philips N.V., UCB Biopharma SRL, Clinical Laserthermia Systems AB, University of California, San Francisco, and NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.

Recent CLPT News & Updates

Narrative Update Jul 10

CLPT: Huntington’s Disease Partnership Will Drive Future Intracranial Procedure Upside

Analysts have lifted their price target on ClearPoint Neuro to $30 from $20, reflecting updated assumptions around a fair value of about $28.33 per share, a modestly lower discount rate, slightly higher modeled revenue growth, and a higher future P/E multiple tied to expectations for more visible revenue opportunities connected to uniQure's AMT-130 program. What’s in the News for ClearPoint Neuro ClearPoint Neuro reaffirmed earnings guidance for 2026 and maintained its expected revenue range of $52 million to $56 million.

Recent updates

No updates